Skip to main content
Erschienen in: Journal of Gastrointestinal Cancer 3/2020

27.05.2020 | Review Article

Predatory Publishers/Journals in Medical Sciences: How to Avoid, Stop, and What to Do after Being Scammed by Them?

verfasst von: Yosef Mohammed-Azzam Zakout

Erschienen in: Journal of Gastrointestinal Cancer | Ausgabe 3/2020

Einloggen, um Zugang zu erhalten

Abstract

Purpose

The phenomenon of predatory publishers and journals is one of the recent issues to affect the scientific field. It has negative impacts upon scientific research and harmful consequences, including the spread of pseudo-medical sciences. This article discusses general outlines regarding the concept of predatory journals to clarify this issue for junior researchers and academic workers.

Methods

A brief description of the mechanism of publication within legitimate journals was highlighted. Moreover, the negative impact of this behavior was clarified along with several suggestions that may help authors to avoid predatory journals. Finally, post-predatory publication procedures were discussed, followed by practical steps to eliminate or minimize this phenomenon.

Conclusion

The practice of publishing in the predatory journals needs to be addressed; raising this topic in all academic and research institutions may help minimize the impacts. Moreover, this topic must be part of the curriculum for both undergraduate and graduate courses to draw students’ attention to this issue. Furthermore, actions should be taken against those who deliberately publish their work in such journals.
Literatur
1.
Zurück zum Zitat Kelly J, Sadeghieh T, Adeli K. Peer review in scientific publications: benefits, critiques, & a survival guide. EJIFCC. 2014;25:227–43.PubMedPubMedCentral Kelly J, Sadeghieh T, Adeli K. Peer review in scientific publications: benefits, critiques, & a survival guide. EJIFCC. 2014;25:227–43.PubMedPubMedCentral
2.
Zurück zum Zitat Sharma H, Verma S. Predatory journals: the rise of worthless biomedical science. J Postgrad Med. 2018;64:226–31.CrossRef Sharma H, Verma S. Predatory journals: the rise of worthless biomedical science. J Postgrad Med. 2018;64:226–31.CrossRef
3.
Zurück zum Zitat Richtig G, Berger M, Lange-Asschenfeldt B, Aberer W, Richtig E. Problems and challenges of predatory journals. J Eur Acad Dermatol Venereol. 2018;32:1441–9.CrossRef Richtig G, Berger M, Lange-Asschenfeldt B, Aberer W, Richtig E. Problems and challenges of predatory journals. J Eur Acad Dermatol Venereol. 2018;32:1441–9.CrossRef
5.
Zurück zum Zitat Beall J. Essential information about predatory publishers and journals. Higher Education in Russia and Beyond. 2016;1:7–9. Beall J. Essential information about predatory publishers and journals. Higher Education in Russia and Beyond. 2016;1:7–9.
6.
Zurück zum Zitat Cobey KD, Lalu MM, Skidmore B, Ahmadzai N, Grudniewicz A, Moher D. What is a predatory journal? A scoping review. 2018;F1000Res, 7:1001. Cobey KD, Lalu MM, Skidmore B, Ahmadzai N, Grudniewicz A, Moher D. What is a predatory journal? A scoping review. 2018;F1000Res, 7:1001.
7.
Zurück zum Zitat Shen C, Björk BC. ‘Predatory’ open access: a longitudinal study of article volumes and market characteristics. BMC Med. 2015;13:230.CrossRef Shen C, Björk BC. ‘Predatory’ open access: a longitudinal study of article volumes and market characteristics. BMC Med. 2015;13:230.CrossRef
8.
Zurück zum Zitat Laine C, Winker MA. Identifying predatory or pseudo-journals. Biochem Med (Zagreb). 2017;27:285–91.CrossRef Laine C, Winker MA. Identifying predatory or pseudo-journals. Biochem Med (Zagreb). 2017;27:285–91.CrossRef
9.
Zurück zum Zitat Cortegiani A, Shafer SL. “Think. Check. Submit.” to avoid predatory publishing. Crit Care. 2018;22:300.CrossRef Cortegiani A, Shafer SL. “Think. Check. Submit.” to avoid predatory publishing. Crit Care. 2018;22:300.CrossRef
10.
Zurück zum Zitat Memon AR. Predatory journals spamming for publications: what should researchers do? Sci Eng Ethics. 2018;24:1617–39.CrossRef Memon AR. Predatory journals spamming for publications: what should researchers do? Sci Eng Ethics. 2018;24:1617–39.CrossRef
11.
Zurück zum Zitat Wilkinson TA, Russell CJ, Bennett WE, Cheng ER, Carroll AE. A cross-sectional study of predatory publishing emails received by career development grant awardees. BMJ Open. 2019;9:e027928.CrossRef Wilkinson TA, Russell CJ, Bennett WE, Cheng ER, Carroll AE. A cross-sectional study of predatory publishing emails received by career development grant awardees. BMJ Open. 2019;9:e027928.CrossRef
12.
Zurück zum Zitat Cobey K. Illegitimate journals scam even senior scientists. Nature. 2017;549:7.CrossRef Cobey K. Illegitimate journals scam even senior scientists. Nature. 2017;549:7.CrossRef
13.
Zurück zum Zitat Memon AR. Publish or perish: a sign 363 of caution for authors to avoid predatory journals. J Pak Med Assoc. 2017;67:822.PubMed Memon AR. Publish or perish: a sign 363 of caution for authors to avoid predatory journals. J Pak Med Assoc. 2017;67:822.PubMed
14.
Zurück zum Zitat Kolata G. Many academics are eager to publish in worthless journals. New York Times. 2017:1–4. Kolata G. Many academics are eager to publish in worthless journals. New York Times. 2017:1–4.
15.
Zurück zum Zitat Memon AR. Revisiting the term predatory open access publishing. J Korean Med Sci. 2019;34:e99.CrossRef Memon AR. Revisiting the term predatory open access publishing. J Korean Med Sci. 2019;34:e99.CrossRef
18.
Zurück zum Zitat Tennant JP. The state of the art in peer review. FEMS Microbiol Lett. 2018;365:fny204.CrossRef Tennant JP. The state of the art in peer review. FEMS Microbiol Lett. 2018;365:fny204.CrossRef
20.
Zurück zum Zitat Memon AR. How to respond to and what to do for papers published in predatory journals? Sci Ed. 2018;5:146–9.CrossRef Memon AR. How to respond to and what to do for papers published in predatory journals? Sci Ed. 2018;5:146–9.CrossRef
21.
Zurück zum Zitat Beall J. Medical publishing triage – chronicling predatory open access publishers. Ann Med Surg (Lond). 2013;2:47–9.CrossRef Beall J. Medical publishing triage – chronicling predatory open access publishers. Ann Med Surg (Lond). 2013;2:47–9.CrossRef
22.
Zurück zum Zitat Eriksson S, Helgesson G. The false academy: predatory publishing in science and bioethics. Med Health Care Philos. 2017;20:163–70.CrossRef Eriksson S, Helgesson G. The false academy: predatory publishing in science and bioethics. Med Health Care Philos. 2017;20:163–70.CrossRef
23.
Zurück zum Zitat Khan G, Moher D. Predatory journals: do not enter. UOJM ePub. 2017:1–5. Khan G, Moher D. Predatory journals: do not enter. UOJM ePub. 2017:1–5.
27.
Zurück zum Zitat Hoffecker L. Cabells scholarly analytics. J Med Libr Assoc. 2018;106:270–2.CrossRef Hoffecker L. Cabells scholarly analytics. J Med Libr Assoc. 2018;106:270–2.CrossRef
28.
Zurück zum Zitat Teixeira da Silva JA, Tsigaris P. What value do journal whitelists and blacklists have in academia? J Acad Librariansh. 2018;44:781–92.CrossRef Teixeira da Silva JA, Tsigaris P. What value do journal whitelists and blacklists have in academia? J Acad Librariansh. 2018;44:781–92.CrossRef
29.
Zurück zum Zitat Mercier E, Tardif P, Moore L, Le Sage N, Cameron PA. Invitations received from potential predatory publishers and fraudulent conferences: a 12-month early-career researcher experience. Postgrad Med J. 2018;94:104–8.CrossRef Mercier E, Tardif P, Moore L, Le Sage N, Cameron PA. Invitations received from potential predatory publishers and fraudulent conferences: a 12-month early-career researcher experience. Postgrad Med J. 2018;94:104–8.CrossRef
32.
Zurück zum Zitat Dobson H. Think. Check. Submit. The campaign helping researchers navigate the scholarly communication landscape. Insights. 2016;29:228–32.CrossRef Dobson H. Think. Check. Submit. The campaign helping researchers navigate the scholarly communication landscape. Insights. 2016;29:228–32.CrossRef
38.
Zurück zum Zitat Dadkhah M, Darbani SM. What can authors do for the papers they published in predatory journals? Pol Arch Med Wewn. 2016;126:574–5.PubMed Dadkhah M, Darbani SM. What can authors do for the papers they published in predatory journals? Pol Arch Med Wewn. 2016;126:574–5.PubMed
39.
Zurück zum Zitat Cappell MS. List predatory journal publications separately from genuine scholarly publications as standard for CVs. BMJ. 2015;350:h2470.CrossRef Cappell MS. List predatory journal publications separately from genuine scholarly publications as standard for CVs. BMJ. 2015;350:h2470.CrossRef
40.
Zurück zum Zitat Moher D, Shamseer L, Cobey KD, Lalu MM, Galipeau J, Avey MT, et al. Stop this waste of people, animals and money. Nature. 2017;549:23–5.CrossRef Moher D, Shamseer L, Cobey KD, Lalu MM, Galipeau J, Avey MT, et al. Stop this waste of people, animals and money. Nature. 2017;549:23–5.CrossRef
41.
Zurück zum Zitat Teixeira da Silva JA, Tsigaris P. Academics must list all publications on their CV. KOME. 2018;6:94–9.CrossRef Teixeira da Silva JA, Tsigaris P. Academics must list all publications on their CV. KOME. 2018;6:94–9.CrossRef
Metadaten
Titel
Predatory Publishers/Journals in Medical Sciences: How to Avoid, Stop, and What to Do after Being Scammed by Them?
verfasst von
Yosef Mohammed-Azzam Zakout
Publikationsdatum
27.05.2020
Verlag
Springer US
Erschienen in
Journal of Gastrointestinal Cancer / Ausgabe 3/2020
Print ISSN: 1941-6628
Elektronische ISSN: 1941-6636
DOI
https://doi.org/10.1007/s12029-020-00418-8

Weitere Artikel der Ausgabe 3/2020

Journal of Gastrointestinal Cancer 3/2020 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.